Structure Therapeutics Inc (GPCR) 뉴스

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies...

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage...

Form 8-K - Current report

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety...

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor...

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks...

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024 

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report